Resources | Article

December 23, 2020

How Does Altis Biosystems Envision the Future of the Pharma/Biopharma Industry?

There is a growing need to address the high failure rate of drug candidates as they progress through clinical trials. Altis Biosystems aims to bring its technological advances to the forefront, enabling the drug development process to more effectively translate results from preclinical experiments to late-stage clinical trials.

November 30, 2020

Enhancing Human Gut Tissue Models through Gene Editing

The variety of normal and diseased human tissues needed to perform comprehensive screening of drug candidates is a key resource for next-generation preclinical models, but obtaining these tissues is challenging. Gene editing enables Altis Biosystems to offer a diverse array of RepliGut® human gut models tailored for specific research programs.

November 10, 2020

Increasing the Efficiency of Drug Development With Preclinical Testing Using Human Intestinal Stem Cells

Due to a lack of robust in vivo gut models, animal studies are generally required to evaluate gut toxicity. However, these studies can be lengthy and expensive and may not accurately recapitulate the behavior of the human gastrointestinal tract. Drugs are thus often developed with undesired gut side effects that are not apparent until clinical trials.

October 22, 2020

Evaluating Microbiome Therapies with Intestinal Cell Models

The microbiome has been shown to play roles in many different disease processes and is implicated in many more, from infectious and gastrointestinal diseases to autoimmune and neurological disorders. Advanced models of the gut leveraging intestinal and colonic stem cells are enabling the development of more reliable and robust systems for evaluating the impact of changes in the microbiome on gut health and screening potential drug candidates, including small molecules, biologics, and live biotherapeutics.

September 29, 2020

Accelerating Drug Development with Microphysiological Systems (MPS)

Current preclinical testing using assays based on cancer cells and animal models often results in high failure rates for drug candidates in the clinic. Microphysiological systems like Altis’s RepliGut™ human intestinal tissue model more accurately reflect human physiological environments, enabling more efficient and cost-effective drug discovery and development.